Substance Use Disorders (SUD)LSDPsilocybinMescaline

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

This study (2015) reviews the evidence on the neuropsychopharmacology of such substances as LSD, psilocybin, and mescaline.

Ask Blossom about this paper

Authors

  • Adam Halberstadt

Published

Behavioural Brain Research
meta Study

Abstract

Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse inhibition of startle, exploratory behavior, and interval timing. Many recent clinical trials have yielded important new findings regarding the psychopharmacology of these substances. Furthermore, the use of modern imaging and electrophysiological techniques is beginning to help unravel how hallucinogens work in the brain. Evidence is also emerging that hallucinogens may possess therapeutic efficacy.

Unlocked with Blossom Pro

Research Summary of 'Recent advances in the neuropsychopharmacology of serotonergic hallucinogens'

Editorial

βBlossom's Take

This review is valuable as a compact statement of where the serotonergic hallucinogen field stood once modern preclinical and imaging tools had started to accumulate. It is especially useful for the way it treats 5-HT2A as the core mechanism while still making room for behavioural assays, human challenge studies and the first hints of therapeutic relevance.

Introduction

Serotonergic hallucinogens — encompassing two main structural classes, the phenylalkylamines and the indoleamines — produce profound alterations in perception, thought, and mood and have been used by humans for thousands of years, though scientific investigation began only in the late nineteenth century. Defining hallucinogens as a pharmacological class proved contentious: standard definitions based on altered consciousness without delirium or addiction were insufficiently specific, leading to the proposal that, in addition to these properties, hallucinogens should bind to the 5-HT2A receptor and produce full substitution for the prototypical agent DOM in drug discrimination paradigms. Despite their structural heterogeneity, phenylalkylamine and indoleamine hallucinogens produce virtually indistinguishable subjective effects, show cross-tolerance with one another, and share a unifying pharmacological mechanism through 5-HT2A receptor activation. This review aimed to synthesise advances in understanding the neuropsychopharmacology of serotonergic hallucinogens, covering receptor pharmacology, validated animal behavioural models, tolerance and cross-tolerance, evidence from human experimental studies, and the role of the prefrontal cortex and its interactions with subcortical structures as a primary site of hallucinogenic drug action.

Methods

This is a comprehensive narrative review that synthesised the preclinical and human experimental literature on serotonergic hallucinogens without formal inclusion/exclusion criteria or quantitative meta-analytic methods. The author covered receptor binding and functional pharmacology — including 5-HT2A and 5-HT2C subtype selectivity — drug discrimination studies using operant conditioning paradigms in rodents, the head twitch response (HTR) assay, prepulse inhibition of startle (PPI), interval timing paradigms, and locomotor activity measures. Human experimental evidence was drawn from challenge studies examining cross-tolerance and subjective effects across compounds. Neurobiological coverage focused on 5-HT2A receptor expression patterns across cortical layers and brain regions, electrophysiological recordings from prefrontal cortex pyramidal neurons in vitro and in vivo, and the organisation of cortico-striato-thalamo-cortical (CSTC) loop circuitry as a substrate for hallucinogen action.

Results

Cross-tolerance studies confirmed that phenylalkylamine and indoleamine hallucinogens mutually substitute in drug discrimination paradigms and produce equivalent blunting of subjective effects following repeated dosing — evidence consistent with a shared receptor mechanism. Multiple converging lines of evidence from in vitro and in vivo work identified 5-HT2A receptor activation as the unitary mechanism responsible for hallucinogenesis: selective 5-HT2A antagonists block hallucinogenic behavioural effects in animals and subjective effects in humans, and highly selective phenylisopropylamine hallucinogens such as DOM produce full substitution for indoleamines in drug discrimination. Electrophysiological investigation identified the prefrontal cortex as a primary site of hallucinogen action. The 5-HT2A receptor is expressed densely in lamina V of the PFC on pyramidal neurons and parvalbumin-positive interneurons. Systemic hallucinogen administration in rats produced a net excitatory effect on PFC pyramidal neurons, with individual cells either excited (38–53%), inhibited (27–35%), or unresponsive. These PFC effects are thought to propagate through CSTC loops involving thalamo-cortical and striato-thalamic circuits to generate the broader pattern of perceptual and cognitive alterations characteristic of hallucinogen action.

Discussion

Convergence of pharmacological, electrophysiological, and human experimental evidence leaves little scientific doubt that 5-HT2A receptor activation is the primary mechanism of classical hallucinogenesis, with the prefrontal cortex — and its dense laminar expression of the receptor on pyramidal neurons — constituting a critical neuroanatomical site of drug action. The net excitatory effect of hallucinogens on PFC pyramidal cells, propagated through CSTC circuitry, offers a plausible neural basis for the disorganised and amplified pattern of cortical activity associated with altered consciousness and perceptual distortion. The resumption of human research with hallucinogens — including brain imaging studies using fMRI, PET, and MEG — has provided additional support for animal and in vitro evidence, and is beginning to elucidate how receptor-level pharmacology translates into circuit-level and behavioural effects. The author identifies understanding of functional selectivity at the 5-HT2A receptor — specifically the relative contributions of G-protein and β-arrestin signalling pathways — as an important avenue for dissociating perceptual from therapeutic effects and for the rational design of functionally selective compounds.

Conclusion

The neuropsychopharmacology of serotonergic hallucinogens is increasingly well characterised: both phenylalkylamine and indoleamine classes produce their subjective and behavioural effects primarily through 5-HT2A receptor activation, with the prefrontal cortex and cortico-striato-thalamo-cortical circuits serving as the principal neuroanatomical substrates. Validated animal models — including drug discrimination, head twitch response, and prepulse inhibition paradigms — have provided essential tools for dissecting receptor mechanisms, and the resumption of controlled human studies is beginning to translate these preclinical insights into neuroimaging and clinical findings. Continued investigation of functional selectivity at the 5-HT2A receptor and the circuit-level consequences of PFC activation holds promise for developing a more complete account of hallucinogen pharmacology and informing the design of novel therapeutic agents.

Study Details

References (33)

Papers cited by this study that are also in Blossom

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)

415 cited
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)

904 cited
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects

Maclean, K. A., Johnson, M. W., Reissig, C. J. et al. · Psychopharmacology (2012)

134 cited
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis

Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)

447 cited
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers: results of an experimental double-blind placebo-controlled study

Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E. et al. · Psychopharmacology (1999)

144 cited
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

1671 cited
Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers

Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)

198 cited
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Griffiths, R. R. · Journal of Psychopharmacology (2008)

878 cited
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

934 cited
Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)

685 cited
Show all 33 references
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

1017 cited
Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors

Carter, O., Burr, D. C., Pettigrew, J. D. et al. · Journal of Cognitive Neuroscience (2006)

233 cited
Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans

Carter, O. L., Hasler, F. ;., Pettigrew, J. D. et al. · Psychopharmacology (2007)

149 cited
Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors

Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)

296 cited
Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)

240 cited
Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT) 2A and 5-HT2C receptors

Moya, P. R., Berg, K. A., Gutiérrez-Hernandez, M. A. et al. · Journal of Pharmacology and Experimental Therapeutics (2007)

136 cited
Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) in rats

Páleníček, T., Fujáková, M., Brunovský, M. et al. · Psychopharmacology (2012)

74 cited
Effects of mescaline and lysergic acid (d-LSD-25)

Hoch, P. H., Cattell, J. P., Pennes, H. H. · American Journal of Psychiatry (1952)

114 cited
Influence of Lysergic Acid Diethylamide (LSD-25) on Subjective Time

Aronson, H., Silverstein, A. B., Klee, G. D. · JAMA Psychiatry (1980)

32 cited
Effects of psilocybin on time perception and temporal control of behaviour in humans

Wittmann, M., Carter, O., Hasler, F. et al. · Journal of Psychopharmacology (2007)

245 cited
The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine

Gillin, J. C., Kaplan, J., Stillman, R. et al. · American Journal of Psychiatry (1976)

123 cited
Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans

Strassman, R. J., Qualls, C. R., Berg, L. M. · Biological Psychiatry (1996)

128 cited
Broadband Cortical Desynchronization Underlies the Human Psychedelic State

Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)

498 cited
Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers

Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)

126 cited
Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography

Riba, J., Anderer, P., Jané, F. et al. · Neuropsychobiology (2004)

131 cited
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

1178 cited
Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin

Carhart-Harris, R. L., Leech, R., Williams, T. M. et al. · British Journal of Psychiatry (2018)

239 cited
Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers

Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)

320 cited
Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin

Bernasconi, F. ;., Schmidt, A. ;., Pokorny, T. ;. et al. · Cerebral Cortex (2013)

62 cited
The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval

Vollenweider, F. X., Csomor, P. A., Knappe, B. et al. · Neuropsychopharmacology (2007)

194 cited
The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations

Kometer, M., Cahn, B. R., Andel, D. et al. · Biological Psychiatry (2011)

98 cited
A review of the clinical effects of psychotomimetic agents

Osmond, H. · Annals of the New York Academy of Sciences (2010)

353 cited
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

744 cited

Cited By (75)

Papers in Blossom that reference this study

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects

Hampsey, E., Martin, K., Kalfas, M. et al. · Journal of Psychopharmacology (2026)

DMT-induced shifts in criticality correlate with self-dissolution

Irrmischer, M., Aqil, M., Luan, L. et al. · Journal of Neuroscience (2025)

Psilocybin alters visual contextual computations

Aqil, M., De Hollander, G., Vreugdenhil, N. et al. · Biorxiv (2025)

1 cited
Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations

Palmisano, V. F., Agnorelli, C., Fagiolini, A. et al. · Biochemistry (2024)

5 cited
Synthetic surprise as the foundation of the psychedelic experience

De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)

13 cited
The Psychedelic N,N-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors

Tyagi, R., Saraf, T. S., Canal, C. E. · ACS Pharmacology and Translational Science (2023)

5 cited
Identification of 5-HT 2A Receptor Signaling Pathways Responsible for Psychedelic Potential

Wallach, J., Cao, A. B., Calkins, M. M. et al. · Biorxiv (2023)

11 cited
Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey

Romeo, B., Fauvel, B., Verroust, V. et al. · Journal of Psychoactive Drugs (2023)

14 cited
Dose-response relationships of LSD-induced subjective experiences in humans

Prugger, J., Hirschfeld, T., Majic, T. et al. · Neuropsychopharmacology (2023)

23 cited
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders

Lewis, V., Bonniwell, E. M., Lanham, J. K. et al. · Cell Reports (2023)

128 cited
Show all 75 papers
More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics

Aqil, M., Roseman, L. · Neuropharmacology (2022)

58 cited
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

Bogenschutz, M. P., Ross, S., Bhatt, S. R. et al. · JAMA Psychiatry (2022)

644 cited
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution

Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)

11 cited
A Multidisciplinary Hypothesis about Serotonergic Psychedelics. Is it Possible that a Portion of Brain Serotonin Comes From the Gut?

Császár, N., Bob, P., Bókkon, I. · Journal of Integrative Neuroscience (2022)

9 cited
Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)

46 cited
A Dose of Creativity: An Integrative Review of the Effects of Serotonergic Psychedelics on Creativity

Costa, M. A. · Journal of Psychoactive Drugs (2022)

6 cited
Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)

11 cited
Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience

Madrid-Gambin, F., Gomez-Gomez, A., Busquets-Garcia, A. et al. · Biomedicine & Pharmacotherapy (2022)

14 cited
Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis

Yu, C. L., Liang, C. S., Yang, F. et al. · Journal of Clinical Medicine (2022)

37 cited
Classic Psychedelic Drugs: Update on Biological Mechanisms

Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)

104 cited
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT

Barker, S. A. · Psychopharmacology (2022)

59 cited
Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation

Barrett, F. S., Zhou, Y., Carbonaro, T. M. et al. · Frontiers in Neuroergonomics (2022)

17 cited
5-HT2CR Is as Important as 5-HT2AR in Inducing Hallucinogenic Effects in Serotonergic Compounds

James Perez Custodio, R., Ortiz, D. M., Lee, H. J. et al. · SSRN (2022)

5 cited
Toward a positive psychology of psychoactive drug use

Arnaud, K. O. S. · Drugs Education Prevention and Policy (2021)

4 cited
Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

Vejmola, Č., Tylš, F., Piorecká, V. et al. · Translational Psychiatry (2021)

39 cited
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)

9 cited
From hallucinations to synaesthesia: a circular inference account of unimodal and multimodal erroneous percepts in clinical and drug-induced psychosis

Leptourgos, P., Bouttier, V., Denève, S. et al. · Psyarxiv (2021)

12 cited
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review

Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)

72 cited
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action

Dos Santos, R. G., Hallak, J. E., Baker, G. et al. · Journal of Psychopharmacology (2021)

49 cited
Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice

Thomas, C. W., Blanco-Duque, C., Breant, B. et al. · Translational Psychiatry (2021)

4 cited
Virtual Reality and Psychedelics for the Treatment of Psychiatric Disease: A Systematic Literature Review

Ortiz, M. I., Gómez-Busto, F. J. · Clinical Neuropsychiatry (2020)

12 cited
Investigation of the Structure-Activity Relationships of Psilocybin Analogues

Klein, A. K., Chatha, M., Laskowski, L. J. et al. · ACS Pharmacology and Translational Science (2020)

101 cited
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review

Ona, G., Bouso, J. C. · Neuroscience and Biobehavioral Reviews (2020)

58 cited
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)

546 cited
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species

Halberstadt, A. L., Chatha, M., Klein, A. K. et al. · Neuropharmacology (2020)

265 cited
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses

Chi, T., Gold, J. A. · Journal of the Neurological Sciences (2020)

94 cited
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Rosenbaum, D., Weissman, C. R., Anderson, T. et al. · Journal of Psychopharmacology (2020)

74 cited
Psychedelics and Psychedelic-Assisted Psychotherapy

Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)

618 cited
Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives

Pallavicini, C., Vilas, M. G., Villarreal, M. et al. · NeuroImage (2019)

66 cited
Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA

Dipasquale, O., Selvaggi, P., Veronese, M. et al. · NeuroImage (2019)

78 cited
Metabolism of lysergic acid diethylamide (LSD): an update

Libânio Osório Marta, R. F. · Drug Metabolism Reviews (2019)

51 cited
The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial

Yanakieva, S., Polychroni, N., Family, N. et al. · Psychopharmacology (2018)

167 cited
Whole-brain multimodal neuroimaging model using serotonin receptor maps explains non-linear functional effects of LSD

Deco, G., Cruzat, J., Cabral, J. et al. · Current Biology (2018)

242 cited
Psychedelics, meditation, and self-consciousness

Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)

401 cited
Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)

Cameron, L. P. · ACS Chemical Neuroscience (2018)

112 cited
Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

184 cited
Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

124 cited
Serotonin and brain function: a tale of two receptors

Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)

727 cited
Dreams and psychedelics: neurophenomenological comparison and therapeutic implications

Kraehenmann, R. · Current Neuropharmacology (2017)

90 cited
Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution

Millière, R. · Frontiers in Human Neuroscience (2017)

215 cited
Modern clinical research on LSD

Liechti, M. E. · Neuropsychopharmacology (2017)

230 cited
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin

Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)

444 cited
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation

Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)

181 cited
The psychological and human brain effects of music in combination with psychedelic drugs

Kaelen, M. · Imperial College London (2017)

10 cited
5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?

Bryson, A., Carter, O., Norman, T. et al. · International Journal of Neuropsychopharmacology (2017)

19 cited
The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation

Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)

399 cited
Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

Halberstadt, A. L. · Current Topics in Behavioral Neurosciences (2017)

116 cited
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways

López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)

299 cited
Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

284 cited
Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging

Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)

108 cited
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)

2144 cited
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)

359 cited
The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens

Canal, C. E., Murnane, K. S. · Journal of Psychopharmacology (2016)

66 cited
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism

Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)

95 cited
Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

197 cited
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)

368 cited
Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics

Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)

25 cited
LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion

Roseman, L., Sereno, M. I., Leech, R. et al. · Human Brain Mapping (2016)

63 cited
Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

875 cited
Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-NN-dimethyltryptamine

Halberstadt, A. L. · Pharmacology Biochemistry and Behavior (2016)

33 cited
Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

1710 cited
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

67 cited
Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

118 cited
Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)

Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)

214 cited
Psychedelics not linked to mental health problems or suicidal behavior: A population study.

Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)

299 cited